CytomX Therapeutics (NASDAQ: CTMX ) is developing two biologics with potential in a range of cancers, one of which has already produced some compelling phase 1 data, and another that will soon produce some phase 1 data. ThisScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclosure:I/we have no s ...